摘要
目的探讨胸腺肽联合MVP方案化疗对非小细胞肺癌患者生存质量的影响。方法50例非小细胞肺癌住院患者均采用MVP（丝裂霉素、长春地辛、顺铂）方案化疗，随机分为实验组（使用胸腺肽α1）和对照组（单纯化疗），化疗前、化疗结束（第2周）后的生存质量采用肺癌患者生存质量量表FACT-L中文版（V4．0）进行评估并比较分析。结果实验组评分数增加值为3．13±2．29，对照组评分数增加值为-1．07±2．19，两者差异有统计学意义（P〈0．01）。结论胸腺肽α1能够改善MVP方案化疗的非小细胞肺癌患者的近期生存质量。
Objective To explore the effect of thymosin and MVP chemotherapy on the life quality of non- small cell lung cancer（NSCLC） patients. Methods 50 cases of NSCLC patients who received MVP（ MMC, VDS, DDP） chemotherapy,were randomly divided into experimental group （using thymosin α1 ） and control group;before chemotherapy and at the end of chemotherapy （ the first 2 weeks） , the quality of life was evaluated and analyzed comparatively by the FACT-L questionnaire of patients with lung cancer-Chinese version （V4.0）. Results The results of the experimental group score increased by （3.13 ± 2.29） ,and control group score increased by（ -1.07 ± 2.19） with significant differences （P 〈 0.01 ）. Conclusions Thymosin α1 can improve the short-term quality of life of the non-small cell lung cancer patients who received MVP chemotherapy.
出处
《中国综合临床》
2009年第11期1160-1161,共2页
Clinical Medicine of China
